紫杉醇联合奈达铂用于ⅠB2~ⅡB期宫颈癌新辅助化疗疗效分析
Paclitaxel combined with nadaplatin in patients with locally advanced cervical cancer
-
摘要:目的 探讨术前紫杉醇联合奈达铂化疗对ⅠB2~ⅡB期宫颈癌的近期疗效。方法 选择2008年3月~2011年3月期间收治的局部晚期宫颈癌患者58例, 分为研究组和对照组, 两组患者经病理确诊后, 研究组给予紫杉醇联合奈达铂的化疗方案并行全麻下广泛全子宫切除和盆腔淋巴结清扫术, 而对照组则在未化疗的情况下直接进行手术, 并对两组患者的临床疗效进行比较分析。结果 研究组31例患者有效率为80.6%, 病理检查提示淋巴结阳性率、阴道切缘阳性率、宫旁累及率、脉管浸润率均较对照组低, 有显著性差异(P < 0.05)。结论 紫杉醇联合奈达铂方案对宫颈癌患者进行新辅助化疗, 可缩小肿瘤体积, 降低肿瘤临床分期, 提高手术率。Abstract:Objective To investigate the efficiency of paclitaxel combined with nadaplatin in locally advanced cervical cancer before operation.Methods A total of 58 patients with locally advanced cervical cancer in our hospital from March 2008 to March 2011 were divided into the study group and the control group.After the definite diagnosis of the patients, the observation group received paclitaxel and nadaplatin chemotherapy concurrent with anesthesia-extensive hysterectomy and pelvic lymph node dissection.The control group underwent surgery directly without chemotherapy.The clinical efficacy in the two groups was analyzed and compared.Results The combination of paclitaxel and nadaplatin can achieve an 80.6% effective therapeutic rate.All patients can then be treated by surgery.The rate of lymphatic vascular space invasion was lower in the study group(i.e., paclitaxel combined with nadaplatin group).Conclusion Stage ⅠB2 to ⅡB bulky cervical cancer can be treated by combined chemotherapy of paclitaxel combined with nadaplatin method before operation.The success rate of operation can be increased.
下载: